We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Trevena GPCR Platform Yields a Novel Mu-Opioid Biased Ligand Analgesic with Side Effect Benefits

News   Jan 24, 2013

 
Trevena GPCR Platform Yields a Novel Mu-Opioid Biased Ligand Analgesic with Side Effect Benefits
 
 
Advertisement
 

RELATED ARTICLES

Trial of Saliva Test for COVID-19 Launched

News

Scientists from the Innovative Genomics Institute (IGI), the same UC Berkeley group that rapidly popped up a state-of-the-art COVID-19 testing laboratory in March, are now trialing a quicker way to obtain patient samples: through saliva.

READ MORE

Asthma Drug Salbutamol Inhibits Tau Filament Formation In Vitro

News

A new study suggests that the common asthma drug called salbutamol may offer potential as a treatment for Alzheimer’s disease. Extensive analytical in vitro experiments show that salbutamol is effective at reducing the accumulation of insoluble fibres of the tau protein – which is found in the brains of people with Alzheimer’s disease.

READ MORE

Switching Immune Cells From “Protect” to “Attack” Mode To Treat Prostate Cancer

News

Researchers found that immune cells called macrophages, which are typically found in prostate cancer tumors to help promote growth, can be rewired to attack the disease using therapeutics.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE